Publicaciones en colaboración con investigadores/as de University of Alberta (7)

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2018

  1. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX

    Haematologica, Vol. 103, Núm. 12, pp. 2088-2096

2017

  1. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631

  2. Health-RELATED quality of life from the MM-003 trial of pomalidomide plus LOW-Dose dexamethasone VERSUS HIGH-DOSE dexamethasone in relapsed and/or refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 2, pp. 63-67

  3. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 9, pp. 519-530